Article

Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study.

Urology and Nephrology Research Center, Shahid Beheshti University, Tehran, Iran.
The Journal of urology (Impact Factor: 3.75). 12/2008; 181(1):252-8. DOI: 10.1016/j.juro.2008.09.003
Source: PubMed

ABSTRACT We evaluated the safety and efficacy of sildenafil citrate for treating erectile dysfunction in patients with multiple sclerosis.
A total of 203 patients with multiple sclerosis (age range 18 to 50 years old) with erectile dysfunction were randomly assigned to receive 50 to 100 mg sildenafil (102 patients in group 1) or a similar regimen of placebo (101 patients in group 2) 45 minutes to 2 hours before sexual stimulation. Patients were asked to use at least 24 doses/attempts at home. Primary outcome measures consisted of responses to questions 3 and 4 from the International Index of Erectile Function questionnaires well as responses to Sexual Encounter Profile diary questions 2 and 3. We also assessed the number of attempts at sexual intercourse, the number of attempts that were successful and adverse drug effects.
Improved erections (positive response to the Global Assessment Questionnaire) were reported by 32.8% of patients receiving sildenafil and 17.6% of those receiving placebo (p = 0.04). For Sexual Encounter Profile question 2 (successful penetration) the increase from baseline in mean per patient percentage of yes responses was 29.4% after sildenafil vs 18.8% after placebo (p = 0.04). The proportion of successful sexual attempts ranged from 12% to 26% for sildenafil and from 9% to 21% for placebo, respectively (p = 0.044). Of patients taking sildenafil and placebo 24 (23.5%) and 9 (8.9%) experienced 81 and 31 adverse events, respectively (p = 0.01).
Compared with placebo, sildenafil has little effect on multiple sclerosis emergent erectile dysfunction and, therefore, cannot be recommended for the routine treatment of erectile dysfunction in patients with multiple sclerosis. This finding implies that there must be other mechanisms that are not affected by sildenafil or are resistant to the effects of sildenafil.

0 Followers
 · 
134 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim was to review the literature on genito-urinary dysfunction in multiple sclerosis (MS).
  • [Show abstract] [Hide abstract]
    ABSTRACT: The range of symptoms which occur in multiple sclerosis (MS) can have disabling functional consequences for patients and lead to significant reductions in their quality of life. MS symptoms can also interact with each other, making their management challenging. Clinical trials aimed at identifying symptomatic therapies have generally been poorly designed and have tended to be underpowered. Therefore, the evidence base for the management of MS symptoms with pharmacologic therapies is not strong and tends to rely upon open-label studies, case reports, and clinical trials with small numbers of patients and poorly validated clinical outcome measures. Recently, there has been a growing interest in the management of MS symptoms with pharmacologic treatments, and better-designed, randomized, double-blind, controlled trials have been reported. This chapter will describe the evidence base predominantly behind the various pharmacologic approaches to the management of MS symptoms, which in most, if not all, cases, requires multidisciplinary input. Drugs routinely recommended for individual symptoms and new therapies, which are currently in the development pipeline, will be reviewed. More interventional therapies related to symptoms that are refractory to pharmacotherapy will also be discussed, where relevant.
    Handbook of Clinical Neurology 01/2014; 122:513-62. DOI:10.1016/B978-0-444-52001-2.00023-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: La dysfonction sexuelle (DS) est un aspect fréquent chez des hommes atteints de sclérose en plaques (SEP). La DS est souvent méconnue parce tant les patients que les médecins hésitent à aborder ces types de problèmes. Des symptômes surviennent dans 50 à 90 % des cas ; parmi eux figurent la dysfonction érectile, la dysfonction éjaculatoire ; la dysfonction orgasmique et une baisse de la libido. La DS peut se manifester à n’importe quel stade de la maladie, sans nécessairement être accompagnée d’infirmités sévères. Alors que la dysfonction érectile (DE) est censée être liée à une lésion spianle, la fatigue, la spasticité et des troubles vésico-sphinctériens sont également en cause dans la DS. En outre, des questions psychosociales et culturelles, dont la dépression, l’anxiété de la performance, et une baisse de l’estime de soi sont à prendre en considération. Une évaluation complète de tous ces aspects est nécessaire. La dysfonction érectile peut être traitée efficacement avec des inhibiteurs de la phosphodiestérase ou des injections intracaverneuses. Le traitement de la dysfonction éjaculatoire comporte la stimulation vibratoire pénienne et la midodrine. En ce qui concerne les questions de fertilité, les effets des immunomodulateurs sur la qualité du sperme sont en majeure partie inconnus, alors que de nombreux traitements avec immunosuppresseurs ont un effet peut-être définitivement négatif sur la qualité du sperme. Des méthodes de procréation assistée représentent parfois la seule option conduisant à la conception. La conscience qu’ont les médecins de ce problème peut contribuer à l’arrivée de traitements appropriés et améliorer la qualité de vie de cette population.
    Annals of Physical and Rehabilitation Medicine 05/2014; DOI:10.1016/j.rehab.2014.05.002